Navigation Links
ClinicalRM Awarded Omnibus III Contracts to Support the Navy Medical Research Center (NMRC)

HINCKLEY, Ohio, Sept. 29, 2011 /PRNewswire/ -- Clinical Research Management, (ClinicalRM) a full-service Contract Research Organization providing services for basic and applied research, clinical trials, and regulatory support, announced today it was awarded two contracts by the Navy Medical Research Center (NMRC) under its Omnibus III program. The awards are for the provision resources in support of NMRC, including: providing an infrastructure of personnel, materials, equipment, facilities, science, and technology that will sustain an acceptable level of medical research.  

ClinicalRM is one of only five other companies to be awarded contracts in both the Full & Open lot (W911QY-11-D-0051), which consists of 14 awardees, and the Small Business Set-Aside lot (W911QY-11-D-0065), which consists of 12 awardees. The contract ceiling for the 5 year Omnibus II program for all awardees is $497 M. The Omnibus III contract is an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract.  

The Omnibus III contract was issued with the intent of facilitating NMRC's mission to conduct R&D across its enterprise, including commands the Navy reports to or supports such as OASD-Health Affairs, JTF, CapMed, and more.  Other branches of the Government will be able to use the contract with approval of the Contracting Office.

"We have a history of providing similar basic and applied biomedical and clinical research expertise to other areas of the government and are extremely pleased to be part of this award to extend our support to the Navy.  Our company's priority is to improve the health and safety of our warfighters and their families through leading medical research," said Victoria Tifft, founder and CEO of ClinicalRM.  Said Tifft, "For 18 years we've proven ourselves as trusted and innovative partners to the U.S. Armed Forces research initiatives, and we look forward to extending that relationship within the Navy Medical Research Center."

Performance under the Omnibus III contract is expected to begin after the new fiscal year starts.  

About the Omnibus III Program

The Omnibus III requirement is to put in place personnel and process infrastructure that will facilitate Navy Medicine's mission to conduct Research & Development (R&D) across its enterprise, including commands that the Navy reports to or supports (e.g., OASD-Health Affairs, JTF CapMed, etc.). In addition to providing personnel, materials, equipment, and facilities (non-construction (bonded), non-Government spaces), this requirement addresses process infrastructure (such as basic university research, vaccine development, clinical trials, or FDA IND application processing).

Navy Medicine provides high quality, economical health care to beneficiaries in wartime and in peacetime. Highly trained Navy Medicine personnel deploy with Sailors and Marines worldwide – providing critical mission support aboard ship, in the air, and on the battlefield. At the same time, Navy Medicine's military and civilian health care professionals are providing care for uniformed services' family members and retirees at military treatment facilities around the globe.

About ClinicalRM

Founded in 1992, ClinicalRM is a full service Contract Research Organization (CRO) specializing in preclinical, and Phase I to Phase IV clinical research, clinical trial support, and product development for biologics, drugs, and devices. ClinicalRM prides itself on providing outstanding customer service and exceeding client expectations.  

ClinicalRM supports its clients with a wide array of regulatory and sponsor services including program and project management, site selection and management, recruitment, clinical data management, safety oversight, statistical analysis and reporting, training, and education within the U.S. and around the globe.  Our commercial, military, Federal and academic customers include: academic research institutions, NIH, Walter Reed Army Institute of Research, U.S. Army Medical Materiel Development Activity, U.S. Army Medical Research Institute of Infectious Diseases, and the Naval Medical Research Center. For more information, please go to:

Dana Stanton
Ph: 800-431-9640   Fax: 800-538-1420
For General Information:

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ClinicalRM (formerly CRM) Awarded $97MM U.S. Army Contract to Support Military Clinical Research for the Warfighter
2. INRS professor Federico Rosei awarded Rutherford Memorial Medal for Chemistry
3. GeoVax Awarded $3.6 Million Grant by U.S. Government for its HIV/AIDS Vaccine Program
4. HumanTouch Awarded 8(a) STARS II GWAC Contract
5. Spatial Integrated Systems, Inc. Awarded Patent for 3D Imaging
6. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
7. Sofie Biosciences is Awarded a DOE Phase I SBIR to Commercialize Microscale Radiochemistry Platform
8. Medical College of Wisconsin and Cellular Dynamics Awarded NHLBI Grant Using Human Induced Pluripotent Stem Cells
9. Roche Building Awarded LEED® Gold Certification
10. Baylor College of Medicine and Texas Childrens Hospital Neuroscientist Dr. Huda Zoghbi Awarded Gruber Neuroscience Prize
11. 2011 Outstanding Young Scientist and Engineer Named; Baltimore City High School Students Awarded Glass Scholarships
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
Breaking Biology News(10 mins):